Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launched

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 12 No 1
Volume 12
Issue 1

WASHINGTON-Marshall Edwards, Inc. has launched a multi-center phase II clinical trial of its anticancer drug phenoxodiol in women with recurrent ovarian and fallopian tube cancers who have failed other forms of chemotherapy.

WASHINGTON—Marshall Edwards, Inc. has launched a multi-center phase II clinical trial of its anticancer drug phenoxodiol in women with recurrent ovarian and fallopian tube cancers who have failed other forms of chemotherapy.

A damaged cell normally shuts off production of the antiapoptotic proteins FLIP and XIAP to allow activation of the apoptosis-triggering receptors (Fas, TNFR1, DR3, TRAIL). Cancer cells resist this process by producing large amounts of blocking proteins such as FLIP. Phenoxodiol blocks FLIP and XIAP in cancer cells without harming noncancer cells, the company said in a news release.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Related Content